Scienture's Q3 Revenue Hits $1.22M, Up 256% on REZENOPY Launch
SCNX sits 25% above its 52-week low of $3.23 on light trading volume (0.2× avg).
Summary
Scienture reported preliminary Q3 2026 revenue of approximately $1.22 million, a 256% sequential jump from Q2's $344,000. The surge reflects the August commercial launch of REZENOPY, its second FDA-approved product, plus initial wholesale shipments and a 74% sequential increase in Arbli wholesale unit sales. This is the first disclosure of Q3 top-line figures and marks a meaningful acceleration from the $343,639 reported in Q2. Management reiterated its goal of profitability in 2027, citing historically high gross margins. Full Q3 results will be filed in the upcoming 10-Q.
At the time of this announcement, SCNX was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $3.23 to $65.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.